TCRX vs. OMER
TCRX (TScan Therapeutics, Inc.) and OMER (Omeros Corporation) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, TCRX returned -30.13%/yr vs 24.05%/yr for OMER. At a 0.19 correlation, their price movements are largely independent.
Performance
TCRX vs. OMER - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TCRX achieves a -7.90% return, which is significantly higher than OMER's -38.98% return.
TCRX
- 1D
- 6.46%
- 1M
- -13.11%
- YTD
- -7.90%
- 6M
- 1.13%
- 1Y
- -36.48%
- 3Y*
- -30.13%
- 5Y*
- —
- 10Y*
- —
OMER
- 1D
- 1.45%
- 1M
- -8.55%
- YTD
- -38.98%
- 6M
- 19.77%
- 1Y
- 228.53%
- 3Y*
- 24.05%
- 5Y*
- -7.58%
- 10Y*
- 0.19%
TCRX vs. OMER - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
TCRX TScan Therapeutics, Inc. | -7.90% | -67.11% | -47.86% | 276.13% | -65.56% | -62.50% |
OMER Omeros Corporation | -38.98% | 73.84% | 202.14% | 44.69% | -64.85% | -53.51% |
Correlation
The correlation between TCRX and OMER is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Jul 16, 2021 | 0.19 |
Fundamentals
TCRX:
$119.65M
OMER:
$665.59M
TCRX:
-$0.96
OMER:
-$0.05
TCRX:
$8.15M
OMER:
$0.00
TCRX:
$6.66M
OMER:
-$10.29M
TCRX:
-$129.32M
OMER:
-$110.44M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TCRX vs. OMER — Risk / Return Rank
TCRX
OMER
TCRX vs. OMER - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for TScan Therapeutics, Inc. (TCRX) and Omeros Corporation (OMER). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TCRX | OMER | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.66 | ||
| Sortino ratioReturn per unit of downside risk | -4.64 | ||
| Omega ratioGain probability vs. loss probability | 0.99 | 1.53 | -0.54 |
| Calmar ratioReturn relative to maximum drawdown | -0.55 | 4.68 | -5.23 |
| Martin ratioReturn relative to average drawdown | -0.79 | 9.51 | -10.29 |
Loading charts...
Drawdowns
TCRX vs. OMER - Drawdown Comparison
The maximum TCRX drawdown since its inception was -93.71%, roughly equal to the maximum OMER drawdown of -95.95%. Use the drawdown chart below to compare losses from any high point for TCRX and OMER.
Loading charts...
Drawdown Indicators
| TCRX | OMER | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.71% | -95.95% | +2.24% |
Max Drawdown (1Y)Largest decline over 1 year | -66.35% | -49.14% | -17.21% |
Max Drawdown (3Y)Largest decline over 3 years | -91.08% | -81.09% | -9.99% |
Max Drawdown (5Y)Largest decline over 5 years | — | -93.37% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -95.95% | — |
Current DrawdownCurrent decline from peak | -93.17% | -60.73% | -32.44% |
Average DrawdownAverage peak-to-trough decline | -72.16% | -48.52% | -23.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 46.35% | 24.16% | +22.19% |
Volatility
TCRX vs. OMER - Volatility Comparison
TScan Therapeutics, Inc. (TCRX) and Omeros Corporation (OMER) have volatilities of 20.61% and 21.12%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TCRX | OMER | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.61% | 21.12% | -0.51% |
Volatility (6M)Calculated over the trailing 6-month period | 51.24% | 73.31% | -22.07% |
Volatility (1Y)Calculated over the trailing 1-year period | 86.11% | 187.05% | -100.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 98.15% | 134.92% | -36.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 98.15% | 110.98% | -12.83% |
Dividends
TCRX vs. OMER - Dividend Comparison
Neither TCRX nor OMER has paid dividends to shareholders.
Financials
TCRX vs. OMER - Financials Comparison
This section allows you to compare key financial metrics between TScan Therapeutics, Inc. and Omeros Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
TCRX and OMER have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
OMER has higher volatility (21.12%) compared to TCRX (20.61%). In terms of maximum drawdown, TCRX dropped -93.71% vs OMER's -95.95%.
OMER currently has the higher Sharpe Ratio (1.23 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TCRX and OMER
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer